On February 9, 2023, Mesoblast Limited (ASX: MSB) announced that their prestigious product, Rexlemestrocel-L, has earned the Regenerative Medicine Advanced Therapy (RMAT) distinction from the US Food and Drug Administration's Office of Tissues and Advanced Therapies. This distinction is given to treatments aimed at addressing chronic low back pain caused by disc degeneration, with hyaluronic acid as the delivery method for injections into the lumbar disc. The RMAT designation was created to expedite the development of regenerative medicine treatments that have the potential to cure, modify, or treat serious illnesses or conditions.
With the RMAT designation, rexlemestrocel-L is eligible for benefits such as a rolling review and a priority review when a Biologics License Application is filed. Mesoblast boasts a robust and extensive global intellectual property portfolio that provides protection until 2041 in key markets. The company's proprietary methods for manufacturing cellular medicines yield a high volume of cryopreserved, ready-to-use products.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
